Skip to content

Retatrutide vs Survodutide

Updated 10 sources

Key differences

  1. 1Survodutide hits GLP-1 and glucagon. Retatrutide adds GIP as a third target.
  2. 2Cross-trial headline numbers: survodutide 16.6% at 76 weeks (SYNCHRONIZE-1, efficacy estimand) vs retatrutide 24.2% at 48 weeks (phase 2). Different trials and analyses.
  3. 3Both are investigational and neither is FDA approved.
  4. 4r/Peptides posters who had anxiety or poor appetite control on retatrutide ask about survodutide as a gentler option. No data backs either way.

Side by side

Facts from each record, in the same words as their own pages.
Retatrutide and Survodutide side by side
RetatrutideSurvodutide
Category
  • GLP-1, Weight loss
  • GLP-1, Weight loss
Evidence
  • Strong human trials
  • Strong human trials
FDA status
  • In clinical trialsRegulatory
  • In clinical trialsRegulatory
WADA
  • Not confirmed
  • Not confirmed
Half-life
  • About 6 days in the phase 1b trial, with exposure rising in proportion to dose. Built for once-weekly shots.Clinical study
  • About 6 to 7 days, an estimate from one guide. We found no published human half-life figure.Competitor guide
Routes
  • Subcutaneous injection
  • Subcutaneous injection
FormsNot reported
  • Vial (powder), Other form
Reported doses
  • 0.25 to 12 mg (subcutaneous injection)
  • 0.3 to 6 mg (subcutaneous injection)
Most cited frequency
  • Once weekly. Start at 2 mg, step up every 4 weeks to a target of 4, 9 or 12 mg, then hold.
  • Once weekly, stepped up to a target of 3.6 or 6.0 mg, then held to week 76
Vial sizes
  • 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
  • 5 mg, 6 mg, 10 mg, 20 mgCompetitor guide
Mixed vial keeps
  • Keep the mixed vial in the fridge and use it within about 28 days.Community-reported
  • Keep the mixed vial in the fridge at 2 to 8 C, away from light, and do not freeze and thaw it.Competitor guide
Protocols on file
  • 18
  • 10

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

10 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Clinical study3

  1. Survodutide delivers 16.6% weight loss in major phase 3 obesity trialPharmaTimes, via a news report · checked Oct 24, 2026
  2. LY3437943, a novel triple agonist, in people with type 2 diabetes: a phase 1b trialThe Lancet · checked Oct 23, 2026
  3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 TrialNew England Journal of Medicine · checked Oct 23, 2026

Regulatory2

  1. Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutideBoehringer Ingelheim (via BioSpace), via a news report · checked Oct 24, 2026
  2. WADA 2026 Prohibited ListWADA · checked Oct 24, 2026

Competitor guide2

  1. Survodutide Dosing Guide: Trial Titration, Reconstitution & Side Effects (2026)Peptide Dosing Protocols · checked Oct 24, 2026
  2. Survodutide dosingPeptide Protocol Wiki · checked Oct 24, 2026

Community-reported1

  1. Anxiety 3X trying Reta. Anyone else try Survodutide?r/Peptides · checked Oct 24, 2026